HEREDITARY ANGIOEDEMA MEDICATION THERAPY:
FIRAZYR® (icatibant, bradykinin B2 inhibitor) subcutaneous
HAEGARDA® (C1 esterase inhibitor) subcutaneous
ORLADEYO™ (berotralstat, kallikrein inhibitor)
TAKHZYRO™ (lanadelumab-flyo, kallikrein monoclonal antibody) subcutaneous

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states’ Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the
HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. Incomplete forms or forms without the chart notes will be returned.

Section A. Acute Attacks of Hereditary Angioedema (HAE):
FIRAZYR® (icatibant, bradykinin B2 receptor antagonist)

Criteria:

- **Criteria for initial therapy:** Firazyr is considered **medically necessary** and will be approved when ALL of the following criteria are met:
  1. Prescriber is a physician specializing in the patient’s diagnosis or is in consultation with an Allergist or Immunologist
  2. Individual is 18 years of age or older
  3. A confirmed diagnosis of acute attacks of angioedema in hereditary angioedema (HAE) that requires on-demand therapy with ALL of the following:
     a. Low C1-inhibitor function
     b. Low C4 level
     c. No urticarial or pruritus
  4. ONE of the following:
     a. Individual has trigger induced acute attacks of angioedema from a known precipitant (e.g., medical, surgical, or dental procedures) but does not require long-term prophylactic therapy
     b. Individual has frequent or severe acute attacks of angioedema despite use of long-term prophylactic therapy
  5. No dual therapy with another agent for treatment of acute attacks of angioedema in HAE unless provider submits justification for dual therapy
  6. No previous life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components

Initial approval duration: 6 months, for a quantity that is enough for treatment of two attacks

- **Criteria for continuation of coverage (renewal request):** Firazyr is considered **medically necessary** and will be approved when ALL of the following criteria are met:
  1. Individual continues to be seen by a physician specializing in the patient’s diagnosis or is in consultation with an Allergist or Immunologist
  2. Individual’s condition has responded while on therapy
     a. Response is defined as: ONE of the following:
HEREDITARY ANGIOEDEMA MEDICATION THERAPY

   i. Achieved and maintains at least a 50% reduction in the number of acute attacks of HAE
   ii. Achieved and maintains at least a 30% in the duration of acute attacks of HAE
   iii. Achieved and maintains at least a 60% reduction in the number of days with acute symptoms

3. No dual therapy with another agent for treatment of acute attacks of angioedema in HAE unless provider submits justification for dual therapy

4. No evidence the individual developed any contraindications or significant unacceptable adverse drug effects that may exclude continued use

Renewal duration: 6 months, for a quantity that is enough for treatment of two attacks

---

Section B. Prophylaxis of Attacks of Hereditary Angioedema (HAE):
HAEGARDA® (plasma derived C1 esterase inhibitor)
ORLADEYO™ (berotralstat, kallikrein inhibitor)
TAKHZYRO™ (lanadelumab-flyo, kallikrein monoclonal antibody)

Criteria:

- **Criteria for initial therapy:** Haegarda, Orladeyo, or Takhzyro is considered *medically necessary* and will be approved when ALL of the following criteria are met:
  1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Allergist or Immunologist
  2. Individual is ONE of the following:
     a. **For Haegarda:** 6 years of age or older
     b. **For Orladayo:** 12 years of age or older
     c. **For Takhzyro:** 12 years of age or older
  3. A confirmed diagnosis of frequent or severe attacks of angioedema in hereditary angioedema (HAE) that requires routine long-term prophylaxis with documentation of ALL of the following:
     a. Low C1-inhibitor function
     b. Low C4 level
     c. No urticarial or pruritus
  4. Individual has failure, intolerance, contraindication or they are not indicated to EITHER danazol or tranexamic acid or aminocaproic acid
  5. No dual therapy with another agent for prevention/prophylaxis of attacks of HAE unless provider submits justification for dual therapy
HEREDITARY ANGIOEDEMA MEDICATION THERAPY

6. No previous life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components

**Initial approval duration:** 6 months

- **Criteria for continuation of coverage (renewal request):** Haegarda, Orladeyo, or Takhzyro is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:

  1. Individual continues to be seen by a physician specializing in the patient’s diagnosis or is in consultation with an Allergist or Immunologist
  2. Individual’s condition has responded while on therapy
     a. Response is defined as: **ONE** of the following:
        i. Achieved and maintains at least a 50% reduction in the number of HAE attacks
        ii. Achieved and maintains at least a 30% in the duration of HAE attacks
        iii. Achieved and maintains at least a 60% reduction in the number of days with symptoms
  3. Individual has been adherent with the medication
  4. No dual therapy with another agent for prevention/prophylaxis of attacks of HAE unless provider submits justification for dual therapy
  5. No evidence the individual developed any contraindications or significant unacceptable adverse drug effects that may exclude continued use

**Renewal duration:** 12 months

- **Firazyr, Haegarda, Orladeyo, or Takhzyro for all other indications not previously listed is considered experimental or investigational** and will not be covered when any one or more of the following criteria are met:

  1. Lack of final approval from the Food and Drug Administration;
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes;
  3. Insufficient evidence to support improvement of the net health outcome;
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
  5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, **but are not limited to:**

  a) Treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration
HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Description:

Hereditary angioedema (HAE) is an autosomal dominant disorder that results from C1 esterase inhibitor (C1INH) deficiency. C1INH regulates the activity of the complement component C1, the first step in the classic complement cascade.

HAE is a disease characterized by recurrent episodes of angioedema, without urticaria or pruritus, most often affecting the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. People with HAE can develop rapid painful swelling of the hands, feet, limbs, face, intestinal tract, or airway. Acute attacks of swelling can occur spontaneously, or can be triggered by stress, surgery, medical or dental procedures, or infection. The swelling is often self-limited and resolves in two to five days without treatment, however laryngeal involvement may cause fatal asphyxiation.

The swelling (i.e., angioedema) that occurs in HAE results from excessive production of bradykinin, a potent mediator of vasodilation. Bradykinin also has important vascular permeability-enhancing effects. During episodes of angioedema individuals with HAE have plasma bradykinin levels shown to be substantially higher than normal.

HAE is caused by low levels or inadequate function of a plasma protein called C1-esterase inhibitor (C1INH) that is involved in regulating how some portions of the immune system and blood clotting pathways work. The absence or dysfunction of C1INH leads to an increase in bradykinin production. Bradykinin dilates blood vessels which is responsible for the symptoms of HAE.

The angioedema of HAE mediated by bradykinin does not respond to epinephrine, antihistamines, or glucocorticoids.

Therapeutic approaches for HAE include both “on-demand” treatments given at the onset of symptoms to abolish angioedema attacks as well as prophylactic treatment used to prevent or minimize attacks. All individuals require a readily available on-demand treatment to terminate unpredictable angioedema episodes. Short-term prophylaxis, is use of medication given before a known trigger such as specific medical or dental procedures. In contrast, long-term prophylaxis is given to decrease the number and length of attacks. An integral part of treatment is trigger avoidance, if possible.

Therapies that are minimally effective or have no benefit at all in the treatment of acute angioedema in HAE include androgens, tranexamic acid, and treatments for allergic (histaminergic) angioedema such as epinephrine. Glucocorticoids and antihistamines are NOT effective for angioedema associated with disorders of C1INH and should not be given once the diagnosis of a C1INH disorder has been made.

Definitions:

Androgens for routine prophylaxis of HAE attacks:

- Danazol
- Oxandrolone
- Oxymetholone
- Methyltestosterone
# HEREDITARY ANGIOEDEMA MEDICATION THERAPY

**Antifibrinolytic agents for routine prophylaxis of HAE attacks:**
- Tranexamic acid
- Aminocaproic acid

Other medications used for treating individuals with HAE:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Age</th>
<th>Route</th>
<th>Self-Administer</th>
<th>Dose</th>
<th>How supplied</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berinert (pdC1INH)</td>
<td>5</td>
<td>IV</td>
<td>Yes</td>
<td>20 IU per kg</td>
<td>500 IU single-use vial</td>
</tr>
<tr>
<td>Firazyr (icatibant) [bradykinin B2 RA]</td>
<td>18</td>
<td>SQ</td>
<td>Yes</td>
<td>30 mg injected to the abdominal area Second dose needed in about 10% of patients and can be given 6 hours after first. <strong>Max of three doses in 24 hours</strong></td>
<td>Single-dose, single-use, prefilled syringe with 30 mg per syringe packaged as single carton with one syringe or pack of three cartons each with one syringe</td>
</tr>
<tr>
<td>Kalbitor (ecallantide) [kallikrein inhibitor]</td>
<td>12</td>
<td>SQ</td>
<td>No</td>
<td>30 mg injected (3 doses of 10 mg each) given at three separate sites. <strong>A second dose can be given within 24 hours after the initial dose</strong></td>
<td>Three 10 mg/mL single-use vials packaged in a carton</td>
</tr>
<tr>
<td>Ruconest (rhC1INH)</td>
<td>13</td>
<td>IV</td>
<td>Yes</td>
<td>&lt; 84 kg: 50 IU per kg ≥ 84 kg: 4200 units (2 vials) Max dose 4200 IU <strong>Second dose rarely needed, no more than two doses in 24 hours</strong></td>
<td>2100 IU single-use vial</td>
</tr>
</tbody>
</table>

**Prophylaxis of HAE**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Age</th>
<th>Route</th>
<th>Self-Administer</th>
<th>Dose</th>
<th>How supplied</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cinryze (pdC1INH)</td>
<td>6</td>
<td>IV</td>
<td>Yes</td>
<td>12 years and older: 1,000 units every 3 or 4 days Up to 2,500 units (100 U/kg) every 3 or 4 days 6-11 years of age: 500 units every 3 or 4 days Up to 1,000 units every 3 or 4 days</td>
<td>500 IU single-use vial</td>
</tr>
<tr>
<td>Haegard (pdC1INH)</td>
<td>6</td>
<td>SQ</td>
<td>Yes</td>
<td>60 IU per kg twice weekly (every 3 or 4 days)</td>
<td>2000 or 3000 IU single-use vials</td>
</tr>
<tr>
<td>Orladeyo (berotralstat) [kallikrein inhibitor]</td>
<td>12</td>
<td>PO</td>
<td>Yes</td>
<td>150 mg orally once daily 110 mg orally once daily in patients with moderate or severe hepatic impairment; persistent GI events; and certain drug-drug interactions</td>
<td>110 mg, 150 mg capsule</td>
</tr>
<tr>
<td>Takhzyro (lanadelumab-flyo) [plasma kallikrein inhibitor]</td>
<td>12</td>
<td>SQ</td>
<td>Yes</td>
<td>300 mg every 2 or 4 weeks</td>
<td>300 mg single-use vial</td>
</tr>
</tbody>
</table>
**HEREDITARY ANGIOEDEMA MEDICATION THERAPY**

**Resources:**


